Medigene AG today announced that it has granted an exclusive, worldwide license for the development and commercialization of its preclinical stage adeno-associated virus-like particles (AAVLPs) technology to 2A Pharma AB.
[pdf-embedder url=”https://2apharma.com/wp-content/uploads/2018/10/Medigene-2A-Pharma-Press-Release-2016-12-20.pdf” title=”Medigene 2A Pharma Press Release 2016-12-20″]
Back